Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Deutsche Boerse AG
  5. SYNLAB AG
  6. News
  7. Summary
    SYAB   DE000A2TSL71

SYNLAB AG

(SYAB)
  Report
Delayed Quote. Delayed Deutsche Boerse AG - 11/26 06:35:35 am
22.8 EUR   +8.57%
11/25SYNLAB : Goldman Sachs maintains a Buy rating
MD
11/25Fitch Affirms Inovie at 'B' after TLB Add-on; Outlook Stable
AQ
11/11SYNLAB : JP Morgan sticks Neutral
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SYNLAB announces upward revision of FY'21 guidance

10/05/2021 | 02:11pm EST

DGAP-Ad-hoc: SYNLAB AG / Key word(s): Results Forecast SYNLAB announces upward revision of FY'21 guidance 05-Oct-2021 / 20:10 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

Following the completion of our full-year forecast and with the July to September period showing higher-than-expected SARS-CoV-2 testing levels, driven by the development of the Delta variant, SYNLAB is raising its FY'21 guidance.

Revenue is now expected to be around EUR 3.5 billion (previously: EUR 3.2-3.3 billion) in FY'21. This represents total growth of 34% (previously: 22-25%) compared with FY'20.

Adjusted EBITDA margin of around 30% is expected in FY'21, leading to an adjusted EBITDA in excess of EUR 1 billion (previously: "exceed EUR 925 million"), compared with EUR 679 million in FY'20.

Unlevered free cash flow (pre-M&A) is expected to be around EUR 700 million in FY'21 (previously: "exceed EUR 500 million") compared with EUR 272 million in FY'20.

SYNLAB will comment on short-term dynamics, including its underlying business performance, and provide further details on its outlook with its non-audited Q3 results, on 10 November 2021.

Statements made in this document may include forward-looking statements. Forward-looking statements include all statements that are not historical facts and can be identified by the use of forward-looking terminology such as the words "believes," "expects," "expected," "may," "will," "would," "should," "seeks," "pro forma," "anticipates," "intends," "plans," "estimates," "estimated," or the negative of any thereof or other variations thereof or comparable terminology, or by discussions of strategy or intentions. These statements are not guarantees of future actions or performance and involve risks, uncertainties and assumptions as to future events that may not prove to be accurate. Actual actions or results may differ materially from what is expressed or forecasted in these forward-looking statements. As a result, these statements speak only as of the date they were made and SYNLAB undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. It should be noted that past performance is not a guide to future performance. Interim results are not necessarily indicative of full-year results. Certain data included in this document (adjusted EBITDA, unlevered free cash flow) are "non-IFRS" measures. For a definition of these measures, please refer to SYNLAB H1'21 press release dated 12 August 2021.

-----------------------------------------------------------------------------------------------------------------------

05-Oct-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

-----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      SYNLAB AG 
              Moosacher Straße 88 
              80809 Munich 
              Germany 
Phone:        +49 1701183753 
E-mail:       ir@synlab.com 
Internet:     www.synlab.com/ 
ISIN:         DE000A2TSL71 
WKN:          A2TSL7 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1238542 
 
End of Announcement  DGAP News Service 
=------------ 

1238542 05-Oct-2021 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1238542&application_name=news

(END) Dow Jones Newswires

October 05, 2021 14:10 ET (18:10 GMT)

All news about SYNLAB AG
11/25SYNLAB : Goldman Sachs maintains a Buy rating
MD
11/25Fitch Affirms Inovie at 'B' after TLB Add-on; Outlook Stable
AQ
11/11SYNLAB : JP Morgan sticks Neutral
MD
11/11SYNLAB : Deutsche Bank reiterates its Buy rating
MD
11/10SYNLAB : Barclays reaffirms its Neutral rating
MD
11/10SYNLAB : Goldman Sachs keeps its Buy rating
MD
11/10SYNLAB : JP Morgan reaffirms its Neutral rating
MD
11/10SYNLAB : Jefferies reaffirms its Buy rating
MD
11/10SYNLAB Boosts FY21 Outlook from IPO Goals
MT
11/10SYNLAB delivers strong 9M 2021 results, on track to significantly exceed 2021 financial..
EQ
More news
Analyst Recommendations on SYNLAB AG
More recommendations
Financials
Sales 2021 3 580 M 4 052 M 4 052 M
Net income 2021 546 M 618 M 618 M
Net Debt 2021 1 555 M 1 760 M 1 760 M
P/E ratio 2021 9,47x
Yield 2021 2,61%
Capitalization 5 067 M 5 733 M 5 734 M
EV / Sales 2021 1,85x
EV / Sales 2022 2,24x
Nbr of Employees 22 000
Free-Float 75,7%
Chart SYNLAB AG
Duration : Period :
SYNLAB AG Technical Analysis Chart | SYAB | DE000A2TSL71 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 22,80 €
Average target price 24,24 €
Spread / Average Target 6,32%
EPS Revisions
Managers and Directors
Mathieu Olivier Floreani Chairman-Management Board & CEO
Sami Badarani Chief Financial Officer & Finance Director
David Raymond Ebsworth Chairman-Supervisory Board
Valor Garcia Santiago Chief Medical Officer
Henrik Andreasen Chief Information Officer
Sector and Competitors